531 related articles for article (PubMed ID: 25303306)
1. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
[TBL] [Abstract][Full Text] [Related]
2. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
3. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.
Schmidt EM; Davies M; Mistry P; Green P; Giddins G; Feldmann M; Stoop AA; Brennan FM
Arthritis Rheum; 2013 Sep; 65(9):2262-73. PubMed ID: 23784528
[TBL] [Abstract][Full Text] [Related]
4. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes.
Goldberg M; Nadiv O; Luknar-Gabor N; Agar G; Beer Y; Katz Y
Mol Immunol; 2009 May; 46(8-9):1854-9. PubMed ID: 19201028
[TBL] [Abstract][Full Text] [Related]
5. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.
Heinhuis B; Koenders MI; van Riel PL; van de Loo FA; Dinarello CA; Netea MG; van den Berg WB; Joosten LA
Ann Rheum Dis; 2011 Apr; 70(4):660-7. PubMed ID: 21187297
[TBL] [Abstract][Full Text] [Related]
6. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Chabaud M; Miossec P
Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
Kang SE; Park JK; Yoo HJ; Kang HS; Park YW; Park BC; Park JE; Lee EY; Lee EB; Song YW
Transl Res; 2021 Jun; 232():75-87. PubMed ID: 33453429
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.
Cho ML; Kim WU; Min SY; Min DJ; Min JK; Lee SH; Park SH; Cho CS; Kim HY
Arthritis Rheum; 2002 Jan; 46(1):42-51. PubMed ID: 11817607
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
11. A recombinant IgG-like bispecific antibody acting as interleukin-1β and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis.
Wang Y; Wu Q; Liu Z; Guo X; Zhou L; Wang Y; Song L; Wang N; Zheng Q; Wang W; Ren G; Li D
Biomed Pharmacother; 2017 May; 89():426-437. PubMed ID: 28249243
[TBL] [Abstract][Full Text] [Related]
12. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
13. Regulation of apoptosis and inflammatory responses by insulin-like growth factor binding protein 3 in fibroblast-like synoviocytes and experimental animal models of rheumatoid arthritis.
Lee HS; Woo SJ; Koh HW; Ka SO; Zhou L; Jang KY; Lim HS; Kim HO; Lee SI; Park BH
Arthritis Rheumatol; 2014 Apr; 66(4):863-73. PubMed ID: 24757139
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Tsurumoto T; Kono M; Shindo H; Ida H; Origuchi T; Eguchi K
J Rheumatol; 2009 Nov; 36(11):2397-402. PubMed ID: 19797510
[TBL] [Abstract][Full Text] [Related]
15. Six-transmembrane epithelial antigen of prostate4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis.
Tanaka Y; Matsumoto I; Iwanami K; Inoue A; Minami R; Umeda N; Kanamori A; Ochiai N; Miyazawa K; Sugihara M; Hayashi T; Goto D; Ito S; Sumida T
Mod Rheumatol; 2012 Feb; 22(1):128-36. PubMed ID: 21633911
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes.
Yamana J; Morand EF; Manabu T; Sunahori K; Takasugi K; Makino H; Yamamura M
Cell Immunol; 2012; 272(2):293-8. PubMed ID: 22055894
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.
Toh ML; Marotte H; Blond JL; Jhumka U; Eljaafari A; Mougin B; Miossec P
Arthritis Rheum; 2006 Jul; 54(7):2109-18. PubMed ID: 16802346
[TBL] [Abstract][Full Text] [Related]
18. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane.
Hosaka K; Ryu J; Saitoh S; Ishii T; Kuroda K; Shimizu K
Cytokine; 2005 Dec; 32(6):263-9. PubMed ID: 16406555
[TBL] [Abstract][Full Text] [Related]
19. Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes.
Kontny E; Grabowska A; Kowalczewski J; Kurowska M; Janicka I; Marcinkiewicz J; Maśliński W
Arthritis Rheum; 1999 Dec; 42(12):2552-60. PubMed ID: 10616000
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
